Online Education

22HT54278 - Advance Care Planning and Advance Directives

August 29, 2022

5:00 PM Eastern, August 29, 2024
The estimated time to complete this activity is 60 minutes.

The activity aims to enable the learner to understand the process of advance care planning, the associated healthcare decision making document aids, and additional resources to assure patient's wishes are elicited and documented in a meaningful manner.

This learning activity provides education on the development of a robust Advance Care Planning (ACP) program and covers the goals, barriers, and enabling strategies to implement an ACP program with patients. This module also offers many ACP resource documents, patient decision aids, and communication tools and techniques for how to facilitate these ACP conversations with patients to honor their wishes when it comes to their goals of care during this period of life.
The content level of this activity is intermediate.

This accredited continuing education activity is designed for physicians, advance practice clinicians, social workers, and nurses caring for patients with bleeding disorders. This activity will additionally target care managers, spiritual care specialists, and other multidisciplinary providers involved in caring for patients with bleeding disorders.

At the conclusion of this activity, the participants should be better able to:

• Discuss complexities and demands of today's older adults to both live and die well?
• Describe various advance care planning program implementation strategies
• Employ completion of advance care planning documents with patients
• Facilitate advance care planning conversations with patients and families using various communication tools and techniques
• Identify advance care planning reimbursement opportunities with CMS and various insurance companies?

• Stephanie VanSlyke, BA, RN, HEC-C

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0? AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.

SOCIAL WORKERS
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credits.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
Internet browser (current version) - Firefox, Safari, Chrome, or Explorer
• Cookies and JavaScript must be enabled in the browser

24HT00069 – The 340B Pharmacy Program and the HTC

January 10, 2024 

5:00 PM Eastern, January 9, 2026
The estimated time to complete this enduring material is 30 minutes.

The purpose of this module is to examine the 340B Pharmacy Program, its role in homecare of hemophilia, eligibility and enrollment, restrictions and requirements, and special considerations for operation of such a program. 

As designated in The Veterans Health Care Act of 1992 designated federally-recognized and federally-funded Hemophilia Diagnostic and Treatment Centers (HTCs) as covered entities eligible to participate in the 340B Drug Pricing Program. HTCs were henceforth able to utilize the 340B Program to stretch federal grant funding and develop capacity to provide robust, comprehensive services to all patients served. In 2015 federal grants divided among 140+ HTCs in the U.S. totaled only $4.9 million from Health Resources and Services Administration (HRSA) (to be used for services not covered by insurance) and an additional $5 million from the Centers for Disease Control and Prevention (CDC) (earmarked for surveillance and research).1 Thus, in this era of fiscal constraint brought on by budget cuts and the effects of federal sequestration, HTC participation in the 340B Pharmacy Program has provided a critical means of financial support for HTC services enabling provision of comprehensive care for all patients seen at HTCs with these programs. Approximately 100 of the 140 HTCs participate in the 340B Pharmacy Program.2 As a condition of participation, these centers must invest all revenues from the program back into patient services, care coordination, research and other programs that directly benefit patients. 

This module will provide a brief history of?the 340B Pharmacy Program established in 1992 under the Veterans Healthcare Act and the role of these programs in lowering costs of care and providing revenue for the HTC which must be reinvested into programs and services provided directly to HTC patients. For those HTCs in consideration of starting a 340B Pharmacy Program, this module also introduces the Office of Pharmacy Affairs requirements and regulations for such a program, including definitions of key terms and information about the application process, program maintenance, and potential program audits. Finally, this module will recommend the Hemophilia Alliance as a resource for HTCs with 340B Pharmacy Programs as well as those who are interested in learning more about the operation and management of such programs at HTCs.? 

This accredited continuing education activity is designed for nurses, pharmacists, pharmacy technicians, and other healthcare professionals in the U.S. Hemophilia Treatment Center (HTC) Network who wish to learn more about establishing and/or managing a 340B Pharmacy Program and the role of these programs in the U.S. HTC Network. 

At the conclusion of this activity, the participants should be better able to:

• Explain homecare provision and the role of the 340B Pharmacy Program 
• Summarize the importance of Section 340B of the Veterans Health Care Act 
• Describe 340B Pharmacy Program eligibility and enrollment 
• Identify restrictions and requirements to operate a 340B Pharmacy Program 
• Discuss special considerations of operating a 340B Pharmacy Program at a federally-recognized U.S. Hemophilia Treatment Center (HTC). 

In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In order for pharmacists/pharmacy technicians to claim credit for their participation in the activity, completion of the activity evaluation survey with inclusion of birth date (mm/dd) and NABP e-Profile ID # is required. UNMC will ensure that the data is provided to CPE Monitor.

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHARMACISTS (PharmDs/RPhs) AND PHARMACY TECHNICIANS  

The University of Nebraska Medical Center designates this activity for 0.5 ACPE contact hours. Pharmacists/Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity.?UAN # JA0000319-9999-24-004-H03-P / UAN # JA0000319-9999-24-004-H03-T 

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 463-238-1186 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT00046 – Understanding Hemophilia

February 24, 2022

5:00 PM Eastern, May 23, 2024
The estimated time to complete this activity is 120 minutes.

"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.

This 6-part online learning activity introduces basic concepts of hemophilia.

Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.

Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.

Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.

Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.

Part 5: Emicizumab covers the novel agent emicizumab, including its indications, mechanism of action, dosing options, lab considerations; as well as management of breakthrough bleeding, the boxed warning of emicizumab, use of emicizumab concurrently with bypassing agents, and potential considerations in the management of persons with hemophilia with or without inhibitors who utilize emicizumab.

Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.

This enduring material is intended for nurses, nurse practitioners, physician assistants, and other clinical staff within the federally recognized U.S. Hemophilia Treatment Center (HTC) network who wish to develop an understanding of basic concepts of hemophilia. The activity is particularly appropriate for clinicians within their first six months of employment at an HTC.

• Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
• Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
• Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
• Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
• Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases

• Jennifer Maahs, MSN, PNP, RN-BC
• Amy Shapiro, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better.
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS

The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

PHYSICIAN ASSISTANTS

University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until May 23, 2024. PAs should only claim credit commensurate with the extent of their participation.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser